GSK Secures FDA Nod for Jideytro in ROS1-Positive Lung Cancer
Event summary
- GSK's Jideytro (zidesamtinib) approved by FDA for ROS1-positive NSCLC patients previously treated with a ROS1 inhibitor, ahead of the September 2026 target date.
- Approval based on ARROS-1 trial showing 44% objective response rate and durable responses in heavily pre-treated patients.
- Jideytro is GSK's first approved lung cancer treatment, acquired from Nuvalent earlier this year.
- GSK advancing additional oncology assets including neladalkib for ALK-altered NSCLC and Ris-Rez for small-cell lung cancer.
The big picture
GSK's approval of Jideytro marks a strategic pivot into lung cancer, complementing its existing focus on blood and women's cancers. The acquisition of Nuvalent bolsters GSK's targeted therapy portfolio, positioning it to compete in the rapidly evolving oncology landscape. With additional assets in development, GSK aims to address unmet needs in NSCLC subtypes, potentially reshaping treatment paradigms.
What we're watching
- Pipeline Expansion
- Whether GSK can sustain momentum with its newly acquired oncology portfolio, particularly neladalkib awaiting FDA review.
- Market Penetration
- The pace at which Jideytro gains market share in the ROS1-positive NSCLC space dominated by existing therapies.
- Execution Risk
- How GSK integrates and advances Nuvalent's pipeline while managing its broader oncology strategy.
Related topics